JOHNSON & JOHNSON (JNJ)

US4781601046 - Common Stock

148.75  +0.97 (+0.66%)

After market: 148.75 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

JOHNSON & JOHNSON

NYSE:JNJ (6/21/2024, 7:07:18 PM)

After market: 148.75 0 (0%)

148.75

+0.97 (+0.66%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-4.32%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap357.99B
Shares
PE14.22
Fwd PE13.49
Dividend Yield3.36%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

JNJ Daily chart

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 152,700 full-time employees. The firm is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company operates through two segments: Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.

Company Info

JOHNSON & JOHNSON

One Johnson & Johnson Plaza

New Brunswick NEW JERSEY 08933

P: 17325242455

CEO: A. Gorsky

Employees: 152700

Website: https://www.jnj.com/

JNJ News

News Imagea day ago - The Motley Fool3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold

The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields.

News Imagea day ago - The Motley Fool2 Top Stocks to Buy Now for Years of Passive Income

These tried-and-true businesses could be wise additions to your portfolio.

News Image2 days ago - Market News VideoNotable Friday Option Activity: TWLO, JNJ, DDOG
News Image2 days ago - Johnson & JohnsonJohnson & Johnson Completes Acquisition of Proteologix, Inc.
News Image3 days ago - USA News GroupBiotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

News Image3 days ago - USA News GroupBiotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/PRNewswire/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of...

JNJ Twits

Here you can normally see the latest stock twits on JNJ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example